• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cancers, Vol. 15, Pages 2077: Presence of Multi-Morbidities and Colorectal Cancer Screening Utilization among Breast Cancer Survivors
Conclusion: Among breast cancer survivors, multi-morbidities were positively associated with CRC screening.
Source: Cancers - March 30, 2023 Category: Cancer & Oncology Authors: Meng-Han Tsai Caitlyn Grunert Jacqueline B. Vo Justin X. Moore Avirup Guha Tags: Article Source Type: research

Cancers, Vol. 13, Pages 6203: Acute and Long-Term Outcomes of ST-Elevation Myocardial Infarction in Cancer Patients, a & lsquo;Real World & rsquo; Analysis with 175,000 Patients
Conclusion: In this large “real world” data, prognosis after STEMI in cancer patients was markedly reduced but differed widely between cancer types. Of note, no withholding of interventional treatments in cancer patients could be observed.
Source: Cancers - December 9, 2021 Category: Cancer & Oncology Authors: Stefan A. Lange Jannik Feld Leonie K ühnemund Jeanette K öppe Lena Makowski Christiane M. Engelbertz Joachim Ger ß Patrik Dr öge Thomas Ruhnke Christian G ünster Eva Freisinger Holger Reinecke Tags: Article Source Type: research

Incidence and Risk of Various Types of Arterial Thromboembolism in Patients With Cancer
CONCLUSION: In this observational study of an aggregated US patient population, those with newly diagnosed cancer had increased risk of ATE events. This risk was most elevated in a 330-day window around cancer diagnosis and was consistent across different types of ATE and cancer.PMID:33673912 | DOI:10.1016/j.mayocp.2020.05.045
Source: Clinical Colorectal Cancer - March 6, 2021 Category: Cancer & Oncology Authors: Jiasheng Wang Yeseong D Kim Chang H Kim Source Type: research

Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF.
Conclusion: In ROCKET AF, a history of cancer was associated with a higher risk of bleeding and non-cardiovascular death, but not ischemic events. The relative efficacy and safety of rivaroxaban compared with warfarin were not significantly different in patients with and without a history of cancer. The results of this study are exploratory and should be taken in context of the study population, which may not be generalizable to those with advanced malignancy. Further investigation is needed to understand optimal anticoagulation strategies in patients with AF and cancer. PMID: 30219887 [PubMed - as supplied by publisher]
Source: Clinical Genitourinary Cancer - September 14, 2018 Category: Cancer & Oncology Authors: Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR, Melloni C Tags: Eur Heart J Qual Care Clin Outcomes Source Type: research

New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer.
Conclusion Older patients with colorectal cancer are at increased risk of developing CVD and CHF. Diabetes and hypertension interact with chemotherapy to increase the risk of cardiovascular morbidity. Future studies should assess the potential for personalized therapeutic options for those with preexisting morbidities and for structured monitoring for patients with a history of exposure to chemotherapy regimens, as well as explore the management of preexisting comorbidities to address long-term cardiovascular morbidity. PMID: 29337636 [PubMed - as supplied by publisher]
Source: Clinical Colorectal Cancer - January 16, 2018 Category: Cancer & Oncology Authors: Kenzik KM, Balentine C, Richman J, Kilgore M, Bhatia S, Williams GR Tags: J Clin Oncol Source Type: research

Aspirin for Primary Prevention.
Abstract Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the risk of colorectal cancer. Aspirin increases the risk of gastrointestinal and intracranial bleeding. The best available evidence supports initiating aspirin in select populations. In 2016, the US Preventive Services Task Force recommended initiating aspirin for the primary prevention of both cardiovascular disease and colorectal cancer among adults ages 50 to 59 who are at increased risk for cardiovascular disease. Adults 60 to 69 who are at increased cardiovascular disease risk may also benefit. There remains considerable unce...
Source: Clinical Colorectal Cancer - June 5, 2017 Category: Cancer & Oncology Authors: Richman IB, Owens DK Tags: Med Clin North Am Source Type: research

Use and Misuse of Aspirin in Primary Cardiovascular Prevention.
Abstract The use of low-dose aspirin in primary prevention of cardiovascular (CV) events in healthy or apparently healthy people is a widely debated topic. Many arguments indicate that "primary prevention" is only a conventional definition and that the transition from primary to secondary prevention represents a continuum of increasing levels of CV risk. Although there are no direct proofs of a different efficacy of aspirin at different CV risk levels, in low-risk populations aspirin will appear to be less efficient. In fact, the lower number of events occurring in patients at low risk yields lower absolute number...
Source: Clinical Colorectal Cancer - May 6, 2017 Category: Cancer & Oncology Authors: Coccheri S Tags: Clin Med Insights Cardiol Source Type: research

Borderline operability in hepatectomy patients is associated with higher rates of failure to rescue after severe complications
ConclusionsHepatectomy patients meeting BL criteria have an overall post‐hepatectomy mortality rate that is triple that of non‐BL patients. With less clinical reserve, BL patients who suffer SC are at greater risk of post‐hepatectomy death. J. Surg. Oncol. © 2016 Wiley Periodicals, Inc.
Source: Journal of Surgical Oncology - November 2, 2016 Category: Cancer & Oncology Authors: Bradford J. Kim, Ching ‐Wei D. Tzeng, Amanda B. Cooper, Jean‐Nicolas Vauthey, Thomas A. Aloia Tags: Research Article Source Type: research

Task Force Releases Recommendations on Aspirin to Prevent Colon Cancer, Heart Disease
By Stacy SimonRESOURCES: Aspirin and Cancer Prevention: What the Research Really Shows The United States Preventive Services Task Force (USPSTF) has published new recommendations about aspirin to help prevent cardiovascular disease (heart attacks and strokes) and colorectal cancer (commonly called colon cancer).The USPSTF says people who are ages 50-59 years, who have at least a 10% risk of developing cardiovascular disease within the next 10 years, and who have no increased risk for bleeding should take low-dose aspirin regularly to help prevent heart attack, stroke, and colon cancer. Candidates should also have a l...
Source: American Cancer Society :: News and Features - April 11, 2016 Category: Cancer & Oncology Tags: Colon/Rectum Cancer Source Type: news

USPSTF publishes recommendation on taking aspirin to prevent heart attack, stroke, and colorectal cancer
(American College of Physicians) The US Preventive Services Task Force recommends that people who are 50-69 years old, have increased risk of cardiovascular disease (CVD), and who are not at increased risk for bleeding, consider taking aspirin for primary prevention of CVD and colorectal cancer. The full recommendation and evidence reviews are published in Annals of Internal Medicine.
Source: EurekAlert! - Cancer - April 11, 2016 Category: Cancer & Oncology Source Type: news

Effect of folic acid supplementation on cancer risk among adults with hypertension in China: A randomized clinical trial
This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - March 17, 2016 Category: Cancer & Oncology Authors: Xianhui Qin, Lin Shen, Rong Zhang, Youbao Li, Xiaobin Wang, Binyan Wang, Xiaodong Jiang, Hua Jiang, Yu Lei, Fan Fan Hou, Jin Gu, Yong Huo Tags: Research Article Source Type: research

Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment.
CONCLUSIONS: Variations in patients' willingness to tolerate different treatment-related adverse events underscore the need for improved communications between physicians and patients about the risks and benefits of their medical treatment, which helps make a more personalized decision for metastatic CRC treatment. PMID: 26577827 [PubMed - as supplied by publisher]
Source: Clinical Colorectal Cancer - November 18, 2015 Category: Cancer & Oncology Authors: Fu AZ, Graves KD, Jensen RE, Marshall JL, Formoso M, Potosky AL Tags: J Cancer Res Clin Oncol Source Type: research

Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment
Conclusions Variations in patients’ willingness to tolerate different treatment-related adverse events underscore the need for improved communications between physicians and patients about the risks and benefits of their medical treatment, which helps make a more personalized decision for metastatic CRC treatment.
Source: Journal of Cancer Research and Clinical Oncology - November 18, 2015 Category: Cancer & Oncology Source Type: research